Are investors missing the point on the STORM trial results?
From today's Roth update on the STORM interim results
"Study summary:
• Multi-dose intravenous administration to patients in Cohorts 1 and 2 was generally well tolerated
• At present no Grade 2, 3 or 4 product-related AEs have been observed • All patients have produced robust anti-viral immune responses
• A number of patients have exhibited signs of possible tumor specific secondary viral replication
• Escalating viral dose has been associated with increased anti-tumor activity on some individual lesions
• Multi-dosing of patients in Cohort 3 continues"
and
"As dose escalation continues in this study, there have been early signs of tumor responses (investigator assessed) including one patient with metastatic bladder cancer in Cohort 2 (first figure below) and a patient with castrate resistant prostate cancer (second figure below). The first patient saw a 23% reduction in the size of a major lymph node between Day 0 and Day 83 and the second patient saw a 35% reduction in a major lymph node between Day 0 and Day 42."
From only 6 patients, 2 have already had good results on the lower dose cohorts. Pretty exciting in my book. Looking forward to see cohort 3 results.
VLA Price at posting:
44.5¢ Sentiment: None Disclosure: Held
